The US Association for Accessible Medicines has praised the US Department of Health and Human Services and the Center for Medicare & Medicaid Services for their recommendation that health plans be required to place generic and branded drugs on their own specialized tiers as part of the Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment Parameters for 2024.
“In spite of the lower prices of generics and biosimilars, plan design too often does not optimize their use. And when this occurs, patients are forced to pay more than necessary,” noted AAM interim CEO David Gaugh. “We look forward to working with the CMS to ensure that patients have access to and realize the full value of lower cost generic and biosimilar medicines
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?